{"protocolSection":{"identificationModule":{"nctId":"NCT02712424","orgStudyIdInfo":{"id":"29001"},"organization":{"fullName":"Dartmouth-Hitchcock Medical Center","class":"OTHER"},"briefTitle":"DAR-901 TB Booster Vaccine to Prevent TB in Adolescents","officialTitle":"A Phase 2, Randomized, Placebo-Controlled, Double-Blind, Study of the Prevention of Infection With Mycobacterium Tuberculosis Among Adolescents Who Have Previously Received BCG","acronym":"DAR-PIA"},"statusModule":{"statusVerifiedDate":"2021-04","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2016-03"},"primaryCompletionDateStruct":{"date":"2020-02-01","type":"ACTUAL"},"completionDateStruct":{"date":"2020-02-01","type":"ACTUAL"},"studyFirstSubmitDate":"2016-03-14","studyFirstSubmitQcDate":"2016-03-14","studyFirstPostDateStruct":{"date":"2016-03-18","type":"ESTIMATED"},"resultsFirstSubmitDate":"2021-02-10","resultsFirstSubmitQcDate":"2021-04-17","resultsFirstPostDateStruct":{"date":"2021-05-11","type":"ACTUAL"},"lastUpdateSubmitDate":"2021-04-17","lastUpdatePostDateStruct":{"date":"2021-05-11","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"PRINCIPAL_INVESTIGATOR","investigatorFullName":"C. Fordham von Reyn","investigatorTitle":"Professor of Medicine","investigatorAffiliation":"Dartmouth-Hitchcock Medical Center"},"leadSponsor":{"name":"Dartmouth-Hitchcock Medical Center","class":"OTHER"},"collaborators":[{"name":"Muhimbili University of Health and Allied Sciences","class":"OTHER"}]},"oversightModule":{"oversightHasDmc":true},"descriptionModule":{"briefSummary":"DAR-901 booster vaccine or placebo will be administered to adolescents in Tanzania primed with BCG to determine if immunization reduces the risk of TB infection","detailedDescription":"DAR-901 whole cell booster vaccine to prevent TB infection in adolescents (\"DAR-PIA\")\n\nThis is a Phase II, 3-injection, randomized, controlled trial of DAR-901 to be conducted in 13-15 year old adolescents in Tanzania previously immunized with BCG. DAR-901 is a whole cell inactivated non-tuberculous mycobacterial vaccine manufactured from the Master Cell Bank of SRL-172 that was used in the successful Phase III DarDar Trial in Tanzania. The goals are to establish the safety and efficacy of DAR-901 in preventing infection with TB. The 1 mg dose was selected during the current Phase I dose-escalation trial of DAR-901 in the US being conducted by Dartmouth and Aeras. The 1 mg dose corresponds to the dose of SRL 172 used in the DarDar Trial.\n\nAll subjects will be screened by the T-spot® IGRA (Oxford Immunotec, Oxford, England) for evidence of TB infection. All screened subjects will have a structured interview to identify risk factors for TB infection (=positive IGRA). IGRA-positive subjects will be referred for further evaluation and will not be entered in the immunization phase of the trial.\n\nIt is estimated that 1000 adolescents will need to be screened to identify a total of 650 IGRA-negative adolescents in the immunization phase of the trial. Subjects will be and randomized 1:1 to DAR-901 or saline control at 0, 2 and 4 months. Doses will be administered by intradermal (ID) injection in the deltoid area. IGRA testing will be repeated before dose 2, at 14 months, and again at 24 months.\n\nThis three year study began in the first quarter of 2016 in Dar es Salaam, is funded by GHIT-Japan and will be directed by Geisel School of Medicine at Dartmouth (PI, F. von Reyn) with collaborators at Muhimbili University of Health and Allied Sciences (MUHAS) in Tanzania and Tokyo Medical and Dental University in Japan."},"conditionsModule":{"conditions":["Tuberculosis"],"keywords":["Vaccine"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE2"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"PREVENTION","maskingInfo":{"masking":"QUADRUPLE","whoMasked":["PARTICIPANT","CARE_PROVIDER","INVESTIGATOR","OUTCOMES_ASSESSOR"]}},"enrollmentInfo":{"count":625,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"DAR-901","type":"ACTIVE_COMPARATOR","description":"0.1 mL intradermal injection of 1 mg DAR-901","interventionNames":["Biological: DAR-901"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","description":"0.1 mL intradermal injection of sterile saline for human use","interventionNames":["Biological: Sterile saline placebo"]}],"interventions":[{"type":"BIOLOGICAL","name":"DAR-901","armGroupLabels":["DAR-901"]},{"type":"BIOLOGICAL","name":"Sterile saline placebo","armGroupLabels":["Placebo"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"New Infection With Mycobacterium Tuberculosis","description":"New infection with TB is based on conversion of IGRA","timeFrame":"3 years"}],"secondaryOutcomes":[{"measure":"Persistent New Infection With M. Tuberculosis","description":"New positive IGRA that is also positive on repeat ≥3 mos later","timeFrame":"3 years"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria: Negative IGRA at baseline -\n\nExclusion Criteria: Pregnancy, serious underlying disease\n\n\\-","healthyVolunteers":true,"sex":"ALL","minimumAge":"13 Years","maximumAge":"15 Years","stdAges":["CHILD"]},"contactsLocationsModule":{"overallOfficials":[{"name":"C Fordham von Reyn, MD","affiliation":"Dartmouth-Hitchcock Medical Center","role":"PRINCIPAL_INVESTIGATOR"}],"locations":[{"facility":"Muhimbili University of Health and Allied Sciences","city":"Dar es Salaam","country":"Tanzania","geoPoint":{"lat":-6.82349,"lon":39.26951}}]},"referencesModule":{"references":[{"pmid":"33004239","type":"DERIVED","citation":"Munseri P, Said J, Amour M, Magohe A, Matee M, Rees CA, Mackenzie T, Tvaroha S, Bailey-Kellogg C, Maro I, Wieland-Alter W, Adams LV, Horsburgh CR, Nakamura K, Arbeit RD, Pallangyo K, von Reyn CF. DAR-901 vaccine for the prevention of infection with Mycobacterium tuberculosis among BCG-immunized adolescents in Tanzania: A randomized controlled, double-blind phase 2b trial. Vaccine. 2020 Oct 27;38(46):7239-7245. doi: 10.1016/j.vaccine.2020.09.055. Epub 2020 Sep 29."},{"pmid":"32811463","type":"DERIVED","citation":"Rees CA, Pineros DB, Amour M, Munseri P, Said J, Magohe A, Matee M, Pallangyo K, von Reyn CF. The potential of CBC-derived ratios (monocyte-to-lymphocyte, neutrophil-to-lymphocyte, and platelet-to-lymphocyte) to predict or diagnose incident TB infection in Tanzanian adolescents. BMC Infect Dis. 2020 Aug 18;20(1):609. doi: 10.1186/s12879-020-05331-w."}]}},"resultsSection":{"participantFlowModule":{"groups":[{"id":"FG000","title":"DAR-901","description":"0.1 mL intradermal injection of 1 mg DAR-901\n\nDAR-901"},{"id":"FG001","title":"Placebo","description":"0.1 mL intradermal injection of sterile saline for human use\n\nSterile saline placebo"}],"periods":[{"title":"Overall Study","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"315"},{"groupId":"FG001","numSubjects":"310"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"281"},{"groupId":"FG001","numSubjects":"278"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"34"},{"groupId":"FG001","numSubjects":"32"}]}],"dropWithdraws":[{"type":"Lost to Follow-up","reasons":[{"groupId":"FG000","numSubjects":"34"},{"groupId":"FG001","numSubjects":"32"}]}]}]},"baselineCharacteristicsModule":{"groups":[{"id":"BG000","title":"DAR-901","description":"0.1 mL intradermal injection of 1 mg DAR-901\n\nDAR-901"},{"id":"BG001","title":"Placebo","description":"0.1 mL intradermal injection of sterile saline for human use\n\nSterile saline placebo"},{"id":"BG002","title":"Total","description":"Total of all reporting groups"}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"315"},{"groupId":"BG001","value":"310"},{"groupId":"BG002","value":"625"}]}],"measures":[{"title":"Age, Categorical","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"<=18 years","measurements":[{"groupId":"BG000","value":"315"},{"groupId":"BG001","value":"310"},{"groupId":"BG002","value":"625"}]},{"title":"Between 18 and 65 years","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]},{"title":">=65 years","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]}]}]},{"title":"Age, Continuous","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"years","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"14.1","spread":"0.76"},{"groupId":"BG001","value":"14.2","spread":"0.75"},{"groupId":"BG002","value":"14.15","spread":".755"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"192"},{"groupId":"BG001","value":"169"},{"groupId":"BG002","value":"361"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"123"},{"groupId":"BG001","value":"141"},{"groupId":"BG002","value":"264"}]}]}]},{"title":"Race (NIH/OMB)","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"American Indian or Alaska Native","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]},{"title":"Asian","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]},{"title":"Native Hawaiian or Other Pacific Islander","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]},{"title":"Black or African American","measurements":[{"groupId":"BG000","value":"315"},{"groupId":"BG001","value":"310"},{"groupId":"BG002","value":"625"}]},{"title":"White","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]},{"title":"More than one race","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]},{"title":"Unknown or Not Reported","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]}]}]},{"title":"Region of Enrollment","paramType":"NUMBER","unitOfMeasure":"participants","classes":[{"title":"Tanzania","categories":[{"measurements":[{"groupId":"BG000","value":"315"},{"groupId":"BG001","value":"310"},{"groupId":"BG002","value":"625"}]}]}]},{"title":"IGRA negative","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"315"},{"groupId":"BG001","value":"310"},{"groupId":"BG002","value":"625"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"New Infection With Mycobacterium Tuberculosis","description":"New infection with TB is based on conversion of IGRA","populationDescription":"Conversion from IGRA neg to pos","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"3 years","groups":[{"id":"OG000","title":"DAR-901","description":"0.1 mL intradermal injection of 1 mg DAR-901\n\nDAR-901"},{"id":"OG001","title":"Placebo","description":"0.1 mL intradermal injection of sterile saline for human use\n\nSterile saline placebo"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"315"},{"groupId":"OG001","value":"310"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"19"},{"groupId":"OG001","value":"18"}]}]}]},{"type":"SECONDARY","title":"Persistent New Infection With M. Tuberculosis","description":"New positive IGRA that is also positive on repeat ≥3 mos later","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"participants","timeFrame":"3 years","groups":[{"id":"OG000","title":"DAR-901","description":"0.1 mL intradermal injection of 1 mg DAR-901\n\nDAR-901"},{"id":"OG001","title":"Placebo","description":"0.1 mL intradermal injection of sterile saline for human use\n\nSterile saline placebo"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"315"},{"groupId":"OG001","value":"310"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"5"}]}]}]}]},"adverseEventsModule":{"frequencyThreshold":"5","timeFrame":"3 years","eventGroups":[{"id":"EG000","title":"DAR-901","description":"0.1 mL intradermal injection of 1 mg DAR-901\n\nDAR-901","deathsNumAffected":0,"deathsNumAtRisk":315,"seriousNumAffected":6,"seriousNumAtRisk":315,"otherNumAffected":126,"otherNumAtRisk":315},{"id":"EG001","title":"Placebo","description":"0.1 mL intradermal injection of sterile saline for human use\n\nSterile saline placebo","deathsNumAffected":0,"deathsNumAtRisk":310,"seriousNumAffected":3,"seriousNumAtRisk":310,"otherNumAffected":142,"otherNumAtRisk":310}],"seriousEvents":[{"term":"Tuberculosis","organSystem":"Infections and infestations","assessmentType":"SYSTEMATIC_ASSESSMENT","notes":"Active TB was defined as an SAE for purpose of this study","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":315},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":310}]},{"term":"Tonsillitis","organSystem":"Infections and infestations","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":315},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":310}]},{"term":"Urinary tract infection","organSystem":"Infections and infestations","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":315},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":310}]},{"term":"HIV infection","organSystem":"Infections and infestations","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":315},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":310}]},{"term":"Cellulitis","organSystem":"Infections and infestations","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":315},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":310}]}],"otherEvents":[{"term":"Infections and infestations","organSystem":"Infections and infestations","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":73,"numAffected":73,"numAtRisk":315},{"groupId":"EG001","numEvents":310,"numAffected":69,"numAtRisk":310}]},{"term":"Other","organSystem":"General disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":53,"numAffected":53,"numAtRisk":315},{"groupId":"EG001","numEvents":73,"numAffected":73,"numAtRisk":310}]}]},"moreInfoModule":{"certainAgreement":{"piSponsorEmployee":false,"restrictiveAgreement":false},"pointOfContact":{"title":"Dr C Fordham von Reyn","organization":"Geisel School of Medicine","email":"fvr@dartmouth.edu","phone":"6036505000"}}},"documentSection":{"largeDocumentModule":{"largeDocs":[{"typeAbbrev":"Prot","hasProtocol":true,"hasSap":false,"hasIcf":false,"label":"Study Protocol","date":"2018-01-01","uploadDate":"2021-02-10T08:11","filename":"Prot_000.pdf","size":2050886},{"typeAbbrev":"SAP","hasProtocol":false,"hasSap":true,"hasIcf":false,"label":"Statistical Analysis Plan","date":"2019-11-25","uploadDate":"2021-02-09T19:03","filename":"SAP_001.pdf","size":2886788}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2026-11-09"},"conditionBrowseModule":{"meshes":[{"id":"D014376","term":"Tuberculosis"}],"ancestors":[{"id":"D009164","term":"Mycobacterium Infections"},{"id":"D000193","term":"Actinomycetales Infections"},{"id":"D016908","term":"Gram-Positive Bacterial Infections"},{"id":"D001424","term":"Bacterial Infections"},{"id":"D001423","term":"Bacterial Infections and Mycoses"},{"id":"D007239","term":"Infections"}]}},"hasResults":true}